Many patients with diabetes are under sub-optimal glycemic control. Central to the clinician�s task in improving glycemic control is the management of hypoglycemic medication therapy, including the use of drugs such as insulin and sulfonylureas. Clinical trials have demonstrated that more intensive hypoglycemic medication therapy results in improved glycemic control. Yet quality measures for this critical process of care have not been developed and we know little about how physicians actually manage hypoglycemic medications.

Background:

Many patients with diabetes are under sub-optimal glycemic control. Central to the clinician�s task in improving glycemic control is the management of hypoglycemic medication therapy, including the use of drugs such as insulin and sulfonylureas. Clinical trials have demonstrated that more intensive hypoglycemic medication therapy results in improved glycemic control. Yet quality measures for this critical process of care have not been developed and we know little about how physicians actually manage hypoglycemic medications.

Objectives:

We propose to develop a quality measure that describes the intensity of physicians� hypoglycemic medication therapy. We will then provide feedback to VA physicians regarding their practices and access to experts in diabetes care to determine whether this intervention leads to improvements in glycemic control.

Methods:

The study is divided into two phases. During the first phase we will use existing data to model the decision to increase hypoglycemic medications. At each medical visit, we will determine whether an increase in medication therapy occurred. We will use recursive partitioning to develop a model that identifies patient characteristics at the visit, such as recent laboratory results and diagnoses, associated with the decision to increase therapy. This model assigns a predicted probability of an increase in therapy to each visit. We then use these predictions to define an intensity of hypoglycemic medication therapy for each physician that compares the actual to predicted number of increases over all patient-visits. The second phase will be a randomized trial in which clinicians at experimental sites receive feedback on performance and access to expert opinion while usual care is provided at control sites. Feedback on performance will be provided twice over 6 months. The change in intensity of treatment scores and glycosylated hemoglobin levels pre- and post-intervention at these sites will be compared to performance of primary care physicians at control sites not receiving the intervention.

Status:

Project is ongoing. Phase 1 analyses have been completed. Clinicians have now received two rounds of feedback on their performance and we will be performing the final data collection shortly. One VA site unexpectedly dropped out after they decided to discontinue their research program.

• Berlowitz DR, Ash AS, Glickman M, Friedman RH, Pogach LM, Nelson AL, Wong AT. Developing a quality measure for clinical inertia in diabetes care. Health Serv Res. 2005 Dec;40(6 Pt 1):1836-53.
• Chaudhry SI, Berlowitz DR, Concato J. Do age and comorbidity affect intensity of pharmacological therapy for poorly controlled diabetes mellitus? J Am Geriatr Soc. 2005 Jul;53(7):1214-6.

Inclusion Criteria:

Clinic patients with diabetes

Exclusion Criteria: